Comparison 2. Tafenoquine (TQ) 300 mg single dose versus primaquine (PQ) 15 mg/day for 14 days (chloroquine (CQ)).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Recurrent P vivax parasitaemia by 6 months (intention to treat)	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.80, 1.34]
2.2 Serious adverse events	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [0.70, 2.83]
2.3 Adverse events by type	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.3.1 Any adverse event	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.89, 1.14]
2.3.2 Abdominal pain	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [0.56, 1.97]
2.3.3 Nausea	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.61, 2.13]
2.3.4 Vomiting	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.56, 1.56]
2.3.5 Diarrhoea	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.43 [0.68, 3.01]
2.3.6 Vertigo/dizziness	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.68, 1.55]
2.3.7 Headache	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.56, 1.25]
2.3.8 Arthralgia	2	358	Risk Ratio (M‐H, Fixed, 95% CI)	2.46 [0.39, 15.53]
2.3.9 Rash/pruritus	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.18 [0.70, 1.99]
2.3.10 Myalgia	2	358	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.33, 1.34]
2.3.11 Cough	2	358	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.25, 2.19]
2.3.12 QT prolongation	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.13, 2.09]
2.3.13 Anaemia/drop in haemoglobin	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	2.55 [0.86, 7.60]
2.3.14 High creatinine phosphokinase	2	358	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.39, 3.36]
2.3.15 High alanine aminotransferase	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.39, 2.44]
2.4 Recurrent P vivax parasitaemia by 6 months (per protocol)	3	516	Risk Ratio (M‐H, Fixed, 95% CI)	1.08 [0.83, 1.39]
2.5 Recurrent P vivax parasitaemia by 6 months (worst‐case scenario)	3	747	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.80, 1.27]
2.6 Recurrent P vivax parasitaemia by region – South America	3	516	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.67, 1.15]
2.7 Recurrent P vivax parasitaemia by region – Asia	3	190	Risk Ratio (M‐H, Fixed, 95% CI)	2.88 [1.15, 7.24]
2.8 Recurrent P vivax parasitaemia by region – Africa	1	41	Risk Ratio (M‐H, Fixed, 95% CI)	1.39 [0.32, 5.99]